跳转至内容
Merck
CN
  • Inhibition of multiplication of the prototypic arenavirus LCMV by valproic acid.

Inhibition of multiplication of the prototypic arenavirus LCMV by valproic acid.

Antiviral research (2013-06-06)
Ángela Vázquez-Calvo, Miguel A Martín-Acebes, Juan-Carlos Sáiz, Nhi Ngo, Francisco Sobrino, Juan Carlos de la Torre
摘要

Valproic acid (VPA), a short chain fatty acid commonly used for treatment of neurological disorders, has been shown to inhibit production of infectious progeny of different enveloped viruses including the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). In this study we have investigated the mechanisms by which VPA inhibits LCMV multiplication in cultured cells. VPA reduced production of infectious LCMV progeny and virus propagation without exerting a major blockage on either viral RNA or protein synthesis, but rather affecting the cell release and specific infectivity of LCMV progeny from infected cells. Our results would support the repurposing of VPA as a candidate antiviral drug to combat arenavirus infections.